Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Nascobal

Cyanocobalamin

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Nascobal:

 BioPortfolio Logo
Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009 6th November, 2009 Par Pharmaceutical Companies
-- Metoprolol: For the quarter ended October 3, 2009, net sales of metoprolol succinate were $161.1 million, a decrease of 47% from the second quarter 2009. The decrease was
Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 1st April, 2009 Par Pharmaceutical, Inc.
First and Only Once-weekly, Self-administered Alternative to Injections for Treatment of Vitamin B12 Deficiency WOODCLIFF LAKE, N.J., April 1 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the

This page has been viewed 20 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Nascobal across BioPortfolio, or for Nascobal Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.